

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lal and Owen

Patent No. 7,425,611

Issued: September 16, 2008

Application No. 10/550,651

Filed: September 26, 2005

Confirmation No. 8346

FILED VIA EFS

For: IMMUNOGENIC HIV-1 MULTI-CLADE,
MULTIVALENT CONSTRUCTS AND
METHODS OF THEIR USE

Examiner: Nicole Kinsey White

Art Unit: 1648

Attorney Reference No. 6395-67675-06

FILED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

REQUEST FOR CERTIFICATE OF CORRECTION

The following printing errors were noted in comparing the printed patent with the papers in the attorneys' files:

In the Specification:

In column 1, line 9, "2192)" should read --21(2)--.

In column 1, lines 10-11, "60/458,990" should read --60/458,880--.

In column 3, line 1, "123" should read --β2--.

In column 6, lines 1-2, "of representative" should read --of a representative--.

In column 9, line 38, "between to distinct" should read --between two distinct--.

In column 14, line 57, "cells'" should read --cell's--.

In column 18, line 55, "HV-1 genome" should read --HIV-1 genome--.

In column 33, line 25, "nef Representative" should read --nef. Representative--.

In column 36, line 25, A^x01" should read --A*01--.

Provided herewith is the fee of \$100.00 pursuant to 37 C.F.R. 1.20(a).

The preceding corrections remedy mistakes of a typographical nature and/or minor character. A Certificate of Correction is enclosed to make formal notice of the errors in the referenced patent.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630

cc: Docketing

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,425,611

DATED : September 16, 2008

INVENTOR(S) : Lal and Owen

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

In column 1, line 9, "2192)" should read --21(2)--.

In column 1, lines 10-11, "60/458,990" should read --60/458,880--.

In column 3, line 1, "123" should read --β2--.

In column 6, lines 1-2, "of representative" should read --of a representative--.

In column 9, line 38, "between to distinct" should read --between two distinct--.

In column 14, line 57, "cells'" should read --cell's--.

In column 18, line 55, "HV-1 genome" should read --HIV-1 genome--.

In column 33, line 25, "nef Representative" should read --nef. Representative --.

In column 36, line 25, A[®]01" should read --A*01--.

MAILING ADDRESS OF SENDER:
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. 7,425,611
No. of add'l copies _____
(@ .30 per page)